Why Some People Are GLP-1 Drug Super-Responders-and Others See No Effect
Clinical variability in GLP-1 receptor agonist efficacy, where patient weight loss outcomes range from negligible to profound, is creating significant forecasting challenges for pharmaceutical giants. While Novo Nordisk (NYSE: NVO) ... Read More